跳至主要内容
临床试验/IRCT2015041521779N1
IRCT2015041521779N1已完成3 期

The effect of adding pyridostigmine to second generation antipsychotic drugs on schizophrenia symptoms: A double blind randomised placebo controlled clinical trial

Vice Chancellor for Research of Jondi Shapour University Of Medical Sciences of Ahvaz0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 40 years(—)
性别
All

入选标准

  • The main inclusion criteria is having schizophrenia disorder.inclusion criteria: The average age between 20 to 40 years and knowing persian language and having consent of participation in this research and having no brain organic disease and using no any anti depressants such as tricyclics drugs and donepezi drug.
  • Exclusion criteria :demensia and severe organic disease and very old age and young age and other neurologic diseases that patients must use anticholinesterase drugs and use of tricyclic antidepressants and donepezil drug.

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research of Jondi Shapour University Of Medical Sciences of Ahvaz

相似试验